News | ECMO Systems | May 04, 2021

Similar Long-Term Outcomes With and Without ECMO for Mechanically Ventilated COVID-19 Patients

A nurse checking an ECMO system being used to support a critically ill COVID-19 patient at Banner Health in Phoenix. ECMO can offer both hemodynamic support and oxygenation for COVID patients who otherwise cannot get enough pulmonary support from ventilators, or are in danger of organ failure.

A nurse checking an ECMO system being used to support a critically ill COVID-19 patient at Banner Health in Phoenix. ECMO can offer both hemodynamic support and oxygenation for COVID patients who otherwise cannot get enough pulmonary support from ventilators, or are in danger of organ failure.

May 4, 2021 – A new study, presented today at the 2021 American Association for Thoracic Surgery (AATS) 101st annual meeting, found that severely ill COVID-19 (SARS-CoV-2) patients treated with extracorporeal membrane oxygenation (ECMO) did not suffer worse long-term outcomes than other mechanically-ventilated patients. The multidisciplinary team included cardio thoracic surgeons, critical care doctors, medical staff at long-term care facilities, physical therapists and other specialists, and followed patients at five academic centers: University of Colorado; University of Virginia; University of Kentucky; Johns Hopkins University; and Vanderbilt University. 

Survivors of critical illness are at high risk for long-term physical, psychological, and cognitive deficits. ECMO shows promising survival benefit for select patients with COVID-19. However, its impact on long-term recovery was unknown. The study measured physical, psychological, and cognitive deficits in in 46 patients who were cannulated for ECMO compared to a control group of 262 mechanically ventilated patients who did not receive ECMO.

The multi-disciplinary team conducted a retrospective analysis of mechanically ventilated patients with COVID-19 admitted between March and May 2020. Data were available for all mechanically ventilated patients from three sites, while all five sites provided ECMO patient data. Survivors had access to a multi-disciplinary post-intensive care unit recovery clinic for long-term care. Physical, psychological, and cognitive deficits were measured using validated instruments during follow up. Patient characteristics and long-term outcomes were compared based on ECMO status.

The study found no significant difference in survival at discharge (69.6 percent ECMO vs. 69.9 percent non-ECMO.) Of the 215 survivors across both groups, 93.9 percent were residing at home, 16.1 percent had returned to work or usual activity and 26.2 percent were still using supplemental oxygen; these rates did not differ significantly based on ECMO status. Rates of physical, psychological and cognitive deficits did not differ significantly. 

“The initial guidance for ECMO in COVID was helpful and saved a lot of lives, and not to their detriment, which is very encouraging,” explained Jessica Rove, M.D., assistant professor, cardiothoracic surgery at University of Colorado Anschutz Medical Campus, and section chief, cardiac surgery, Rocky Mountain Regional VA Medical Center. “This multidisciplinary collaboration is committed to examining long-term outcomes beyond survival, and early results look promising. This may help to further refine who should receive ECMO and may increase the rate of positive outcomes.” 

Further research will continue to follow patients and measure outcomes over the longer term. 

“It is exciting that we now have the long term outcomes of these patients and that they are so promising," explained Lauren Taylor, M.D., a fellow at University of Colorado Anschutz Medical Campus. "Further study of these patients over the long term can help to further refine who we are canulating for ECMO, leading to better outcomes for all.”

The study "Long-term Recovery of COVID-19 Survivors is Not Negatively Impacted by ECMO: A Multicenter Study from the ORACLE Group," included the following authors:  Lauren J Taylor, Chintan Ramani, Shoaib Fakhri, Kirby P Mayer, Eric W Etchill, Matthew F Mart, Sarah E Jolley, Alexandra Kadl, Skyler Peterson, Ashley A Montgomery-Yates,  Ann M Parker, Carla Sevin, Kathryn Colborn,  Nicholas Teman,  Jordan Hoffman,  Kyle Enfield,  Karsten Bartels, Bo Soo Kim,  Sung-Min Cho, Joseph Hippensteel, Glenn J.R. Whitman,  Joseph B Zwischenberger,  Jessica Y Rove. 

The AATS is the premiere association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. It is more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. 

For more information: www.aats.org
 

Related COVID-19 ECMO Support Content:

COVID Mother Reunited With Caregivers After Saving Her Live With ECMO

Abiomed Adds ECMO Cardiopulmonary Support to its Portfolio

FDA Allows Emergency Use of Impella for COVID-19 Patients on ECMO

VIDEO: ECMO Support Effective in Sickest COVID-19 Patients — Interview with Ryan Barbaro, M.D.,

FDA Approves ECMO to Treat COVID-19 Patients

VIDEO: COVID Survivor on ECMO in Hospital 152 Days Reunited With Clinicians Who Saved Her

ECMO Used to Treat Adult Respiratory Distress Syndrome Case

FDA Allows Emergency Use of Impella for COVID-19 Patients on ECMO

The Cardiovascular Impact of COVID-19

 

 

Related Content

#breakingnews The U.S. Food and Drug Administration (FDA) just granted full approval to the Pfizer/BioNTech Covid-19 vaccine for people age 16 and older. It is the first vaccine to be fully approved by the FDA, and experts say it is expected to open the door for further vaccine mandates.

Getty Images

News | Coronavirus (COVID-19) | August 23, 2021
August 23, 2021 — The U.S.
The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compromised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images #AHA #coronavirus #COVID19

The American Heart Association announced its support this week for the CDC and FDA recommendation that immuno-compormised patients should receive a third dose of the Pfizer or Moderna COVID vaccines. Getty Images

News | Coronavirus (COVID-19) | August 18, 2021 | By Dave Fornell, Editor
August 18, 2021 — The U.S.
In an effort to contain COVID-19 and the new rapid spread of the delta virus across the U.S., a coalition of 10 cardiovascular societies issued a statement of support for healthcare systems requiring COVID-19 vaccines for its employees. ACC, HRS, ASNC, SCMR, SCCT, ASE, HFSA, STS, SCAI.

In an effort to contain COVID-19 and the new rapid spread of the delta virus across the U.S., a coalition of 10 cardiovascular societies issued a statement of support for healthcare systems requiring COVID-19 vaccines for its employees. 

Feature | Coronavirus (COVID-19) | July 30, 2021 | By Dave Fornell, Editor
July 30, 2021 — A coalition of 10 U.S.-based cardiovascular societies have issued a statement today in support of all
AHA president says COVID has a direct impact on the heart and preventive measures for heart disease largely went out the window during the pandemic

Getty Images

News | Coronavirus (COVID-19) | July 26, 2021
July 26, 2021 — Heart disease and stroke continue to kill more people in the U.S.
A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19.

A new study with data from more than 10,000 COVID patients confirmed that patients taking statin medications had a 41 percent lower risk of in-hospital death from COVID-19. Researchers believe statins, which attach to the ACE2 receptors, may block the virus from attaching to these same receptors. 

News | Coronavirus (COVID-19) | July 21, 2021
July 21, 2021 — In a new study from University of California San Diego School of Medicine, researchers have confirmed
New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. How to anticoagulate COVID patients. How to prevent thrombus in COVID patients.

New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. Getty Images
 

Feature | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — COVID-19 is m
Diluting of a blood sample for real-time deformability cytometry testing. Researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen. Germany, were able to show for the first time COVID-19 significantly changes the size and stiffness of red and white blood cells, sometimes over months. From the study How a COVID-19 Infection Changes Blood Cells in the Long Run. Reasons for long COVID.

Diluting of a blood sample for real-time deformability cytometry testing. Researchers at the Max-Planck-Zentrum für Physik und Medizin in Erlangen. Germany, were able to show for the first time COVID-19 significantly changes the size and stiffness of red and white blood cells, sometimes over months.

News | Coronavirus (COVID-19) | July 15, 2021
July 15, 2021 — Using real-time deformability cytometry, researchers at the...
Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

Researchers analyzing surveillance data on 518 children and adolescents with MIS-C who were admitted to U.S. hospitals in 2020 fopiund those treated with intravenous immune globulin (IVIG) plus glucocorticoids had a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. Left photo Getty Images, right photo Nemours Children’s Health System.

News | Coronavirus (COVID-19) | June 28, 2021
June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in child
The U.S. Food and Drug Administration (FDA) announced June 25 it has added a warning on the Moderna and Pfizer COVID-19 messenger RNA (mRNA) vaccine fact sheets to explain they may cause myocarditis in rare cases as a side effect. The agency said the side effect is very rare and patients generally recover quickly, but it can disportionally affect younger patients in their teens and early 20s. Getty Images

Getty Images

News | Coronavirus (COVID-19) | June 28, 2021 | Dave Fornell, Editor
June 28, 2021 — The U.S.
A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP).

A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP). Getty Images

Feature | Coronavirus (COVID-19) | June 24, 2021 | By Dave Fornell, Editor
A small number of patients develop inflammation leading to myocarditis after receiving the messenger RNA (mRNA)...